Sodium Zirconium Cyclosilicate (SZC)
Sponsors
AstraZeneca, Alexandria University, Qianfoshan Hospital
Conditions
Chronic Kidney DiseaseChronic Kidney Disease on HemodialysisHyperkalaemiaHyperkalemiaHypokalemiaMyocardial InjuryRenal Insufficiency, Chronic
Phase 3
Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
TerminatedNCT04847232
Start: 2021-04-30End: 2024-03-07Updated: 2025-06-18
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
TerminatedNCT05056727
Start: 2021-09-30End: 2024-02-07Updated: 2026-01-08
Phase 4
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
TerminatedNCT04997161
Start: 2021-08-17End: 2021-11-17Updated: 2023-01-19
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
CompletedNCT05347693
Start: 2022-03-24End: 2024-12-10Updated: 2025-11-28
The Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients
Not yet recruitingNCT06736184
Start: 2025-03-01End: 2026-12-31Target: 100Updated: 2024-12-16
Unknown Phase
SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients
CompletedNCT06029179
Start: 2024-01-15End: 2024-12-15Updated: 2025-02-11
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
CompletedNCT06185660
Start: 2024-02-09End: 2025-01-03Updated: 2025-12-30